



# Updates of Technical Evaluation Reference Group

## 47<sup>th</sup> Board Meeting

For Board Information

GF/B47/10

10-11-12 May, Geneva / Virtual



# Executive Summary

## Context


- This update shows an overview of TERG work streams.

## Questions addressed in this slide deck

1. Overview and timeline (slide 3)
2. Evaluation of the wambo.org pilot for non-Global Fund-financed orders (slides 4-6)
3. Current status of ongoing evaluations (as of early April) and next steps:
  - C19RM (slide 7);
  - Community engagement and community led response (slide 8); and
  - TB prevention (slide 9).
4. The summary objectives and next steps (as of early April) of additional work streams:
  - Evaluations of data-driven decision making; and accelerating equitable deployment & access to innovation (slide 10);
  - Evaluation of Challenging Operating Environment; and Country-steered Review (formerly 360-degree feedback) (slide 11); and
  - RSSH mapping (slide 12).

**Input Received** – key inputs received from SC and the Secretariat on the draft TORs. Responses to SC inputs are available as background document.

# Timeline



# TERG evaluation of the wambo.org pilot for non-Global Fund-financed orders (1/3)

## Key Messages Arising from Evaluation

---

- Findings from the qualitative and quantitative evaluation data support the **full implementation of wambo.org beyond the pilot phase**. Triangulation of this data demonstrates that the benefits of the wambo.org pilot outweigh the costs and identified risks. More needs to be done to publicize it and possibly incentivize its use.
- The benefits of the pilot include **potential for large savings, enhanced visibility and transparency of the procurement process; ensuring accountability for the buyers; access to quality-assured, competitively priced medicines; use of <http://wambo.org> catalogue for budgeting; lead time estimates to facilitate supply planning leading to lower risk of stockouts; and potential for expanded use if the range of products is increased.**
- The report describes some barriers to use of wambo.org non-grant channel with domestic funds such as the **prepayment requirement, individual countries' procurement legislation, their regulatory framework** which may not include products from wambo.org's portfolio, and Global Fund's eligibility and QA requirements for health products also limit the number of locally manufactured products in the wambo.org catalogue

# TERG evaluation of the wambo.org pilot for non-Global Fund-financed orders (2/3)

## TERG Position

---

The TERG largely endorses the key findings, high-level conclusions and the recommendations of the evaluation. The TERG recommends that the use of wambo.org through domestic funding/non-grant channel should be continued beyond pilot to full implementation, thereby opening wambo.org non-grant channel procurements to all Global Fund countries and those that are moving towards transition with no cap. The following needs to be considered to ensure the success of **full-scale** implementation:

- **Rebrand** (*wambo.org+* or *wambo.org 2*) and mainstream the pilot, which becomes business as usual and not a continuing trial.
- **Design the next phase:** define a straightforward process and operational framework for onboarding new buyers, outline the platform's **value proposition and long-term vision**.
- **Increase advocacy and awareness** around the option for the use of domestic funding through wambo.org: The Global Fund should **assertively** offer wambo.org non-grant channel to current principal recipients (PRs) and potentially to other government and non-government stakeholders in Global Fund countries as it was a targeted and pull approach in its pilot phase implementation. Based on the country case studies and stakeholders' interviews, there is a need for in-country advocacy of policy makers to increase the utilization of the wambo.org platform.

The Strategy Committee (SC) members largely support the TERG position on wambo.org pilot evaluation findings, conclusions and recommendations noting the importance of Global Fund Secretariat to outline a concrete approach to align wambo.org with the support and strengthening of in-country supply chains in the entire value chain and how this is expected to be implemented, including on expansion to health products for Non-Communicable Diseases (NCD), and its alignment with the NextGen Market Shaping approach, in support of the Global Fund 2023-2028 Strategy. A pre-payment mechanism should be discussed, and solutions proposed to overcome the pre-payment requirement which is frequently noted as a barrier for utilization of wambo.org Non-Global Fund Grant Channel (NGC).

# **TERG evaluation of the wambo.org pilot for non-Global Fund-financed orders (3/3)**

## **TERG Strategic and Operational Recommendations**

### **Strategic Recommendations**

1. Redesign, enhance and fully implement wambo.org's non-grant channel (NGC)
2. Explore the possibility of expanding wambo.org's product catalogue to include Non communicable Diseases (NCDs) and other disease areas that impact HTM programs
3. Help support sustainability by establishing and communicating an operational framework for the use of wambo.org non-grant channel for countries transitioning or projected to transition.

### **Operational Recommendations**

1. Design and implement a revised pre-payment mechanism to address regulatory barriers and get wider acceptance from the countries to use wambo.org with domestic funding.
2. Explore how wambo.org can be complemented with capacity building
3. Explore options to bring more visibility to the wambo.org competitive tendering process
4. Promote transparency and in-country data sharing

# Evaluation of C19RM

Summary objectives: 1. Determine relevance, appropriateness and timeliness of C19RM 2020 investments; 2. Analyze effectiveness of C19RM in mitigating the potential impact of the COVID-19 pandemic on the three diseases and on wider public health; 3. Examine efficiency and effectiveness merits of coordinating globally to roll out the C19RM 2020 through the ACT-A partnership; 4. Provide lessons learned for future pandemic response.

---

## 1. Overall progress (as of early April)

- 95% of required documentation has been shared with evaluators.
- 95% of document review is complete.
- 100% global interviews are complete.
- Country Case Study evaluation work progressing according to plan.

## 2. Next steps

- 21 April: Draft report complete.
- Early May: Draft report discussed at TERG meeting.
- Mid May: Final report submitted to TERG.
- July: Final report for SC meeting.



# Evaluation of Community Engagement and Community led Response

Summary objectives: 1. To **assess the design, implementation, and results of CE and CLR** that have been supported by the Global Fund since 2017 and draw out lessons learned; 2. To assess the **contribution of CE and CLR** to the achievement of the GF results; 3. To **draw lessons learned and develop actionable recommendations** to guide 2023–2028 investments and implementation strategies, including possible changes to the Business Model.

---

## 1. Overall progress (as of early April)

- 100% of inception phase interviews completed.
- Inception report submitted.
- More than 60% of relevant documents shared with the evaluation team.
- Selection of 10 countries for case studies completed.

## 2. Next steps

- April/May: Country case studies initiated
- 11 April: Submission of preliminary findings (data collection and analysis phase) to TERG.
- 29 April: Submission of draft synthesis to TERG.
- Early May: Discussion of draft synthesis at the TERG meeting.
- 30 May: Submission of final report to TERG.
- July: Final report for SC meeting.



*The Global Fund/Atul Loke/Panos*



# Evaluation of TB prevention

Summary Objectives: Review the Global Fund policies and processes to support TB prevention programs and propose inputs on how these can be further improved to enhance efforts to prevent TB in the current grants, the next allocation cycle and during the next strategy period. Including an assessment of the scope, scale, and results of GF investment in TB prevention to date with an emphasis on TPT and airborne infection prevention and control as well as working with partners at global and country level.

## 1. Overall progress (as of early April)

- Inception report submitted.
- More than 90% of relevant documents shared with the evaluation team.
- Finalized selection of countries for case studies (CCS) and portfolio analysis. CCS are ongoing
- Preliminary findings update provided to TERG Focal points.

## 2. Next steps

- 15 April: First Draft.
- Mid-May: Present draft preliminary findings at the TERG meeting.
- 3 June: Submission of final report.
- July: Final report for SC meeting.



# Evaluation of Data-driven Decision Making (DDDM)

Jointly conducted with an OIG audit

---

## 1. Summary objectives (more detail in [RFP](#))

- To map the Global Fund (GF) data investments since 2017 and to document the progress in data use for country programs at the country level as a result of all data related investments;
- To identify, using a health system strengthening perspective, gaps, weakness/challenge that need to be overcome to improve use of data for decision-making at the country level for country programs and country-level hindering and enhancing factors;
- To identify potential scalable activities in DDDM at country level and document good practices and concrete examples; and
- To provide recommendations on how the GF model can effectively support DDDM at country level.

## 2. Next steps

- 23 March: RFP closed.
- 20 April-12 May (TBC): inception phase.
- 9 June: TERG meeting.
- July: SC meeting to provide update.
- October: Final report to SC meeting.

# Evaluation of Accelerating Equitable Deployment and Access to Innovation

---

## 1. Summary objectives (more detail in [RFP](#))

- To assess the design, implementation and results including challenges of equitable deployment and access to innovations that have been supported by the Global Fund and other global health actors since 2017;
- To assess the contribution of some of these innovations to the achievement of selected outcomes and results; and
- To draw lessons learned by identifying in-country facilitating/hindering factors in accessing and deploying innovations and develop actionable recommendations to guide 2023–2028 investments and implementation, and baseline indicators.

## 2. Next steps

- 31 March: RFP close.
- Late April: inception phase.
- May/June: TERG meeting.
- July: SC meeting to provide update.
- October: Final report to SC meeting.

# Evaluation of Challenging Operating Environment (COE)

---

## 1. Summary objectives (more detail in [RFP](#))

- Evaluate how the COE policy has been operationalized across the Global Fund COE portfolio and assess how the COE policy contributes to enhancing or impeding the Global Fund strategic and disease priorities, with a view to ascertaining how policy, processes and practice could be improved;
- Evaluate the operationalization of Global Fund COE Policy to assess its implementation against the three principles governing Global Fund investments in COEs, i.e., flexibility, partnerships, and innovation.

## 2. Next steps

- 1 April: RFP closed.
- 11 April TEC meeting
- 18-22 April: inception phase.
- May/June: TERG meeting.
- July: SC meeting to provide update.
- October: Final report to SC meeting.

# Country-steered Review of the Global Fund (Previously 360 Degree Feedback Scoping Exercise)

---

## 1. Summary objectives

- To provide frank, multi-directional insights into how the Global Fund is working at country level through the development, field testing and finalization of a Country-steered Review tool;
- To develop this tool through consultation with implementing country partners (and a range of stakeholders) to provide rigorous feedback on the Global Fund.

This tool would be managed by the new Evaluation Unit as part of the M&E framework and, to ensure impartiality, shall be implemented by an independent, external entity who would report to the SC through the Independent Evaluation Panel.

## 2. Next steps

- 25 April: (re-issued) RFP close .
- 9-20 May: inception phase.
- 8 June: TERG meeting.
- July: SC meeting to provide update.
- October: Final report to SC meeting.

# RSSH Mapping Exercise

Rational for mapping exercise:

Strategy Committee's request to have a better understanding of the Global Fund's overall contribution to the RSSH ecosystem in countries with a particular focus on implementation.

---

## 1. Summary objectives

In collaboration with WHO

1. Analyze Global Fund investments in RSSH by module and its trends and priorities over time;
2. Evaluate comparability of publicly available health expenditure data and its sub-categories (RSSH modules) used by Global Fund with the categorization of Global Health Expenditure Database (GHED), IHP+ and UHC2030 for National Health Sector Strategies, the National Health Accounts and IHME estimates to deliberate on the comparability and reliability of the data across the named sources;
3. Compare trends of Global Fund investments in HSS with development partners and domestic investments (where and if possible) to understand the fit of Global Fund investments and its RSSH modules with the domestic and development partner investments in global level;

4. Assess the relative proportion of Global Fund's HSS grant disbursements in a sample of countries and compare its alignment and contribution (or lack of it) to overall Health Sector Strategic Plan(s) (HSSP) and budgets for 2015 – 2022 (NFM1 through NFM3) period; and
5. Make recommendations that support the operationalisation of RSSH in the new Global Fund strategy which would support better comparability and transparent monitoring of RSSH investments made by Global Funds, other Development Partners and Countries.

## 2. Next steps

- Discussions with WHO on finalizing scope and work modalities.
- May 15: 1st draft report covering objectives 1 – 3
- July: Update to SC.
- October: Final report to SC meeting.